The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux - Full Text View

Sponsored by:	Takeda Global Research & Development Center, Inc.
Information provided by:	Takeda Global Research & Development Center, Inc.
ClinicalTrials.gov Identifier:	NCT00324974

Purpose

This study will assess the safety and efficacy of once daily administration of Lansoprazole Microgranules Oral Suspension in infants with gastroesophageal reflux symptoms during a 4-week treatment period.

Condition	Intervention	Phase
Gastroesophageal Reflux Disease	Drug: Lansoprazole Microgranules suspension Drug: Placebo	Phase III

MedlinePlus related topics: GERD

Drug Information available for: Lansoprazole

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Study Assessing the Safety and Efficacy of Lansoprazole Microgranules Oral Suspension in Infants With Symptomatic Gastroesophageal Reflux

Further study details as provided by Takeda Global Research & Development Center, Inc.:

Primary Outcome Measures:

Percentage of subjects in each treatment group responding to treatment with a reduction from baseline in the percentage and duration of crying/fussing/irritability episodes associated with feeding after 4 weeks of treatment. [ Time Frame: Week 4 ] [ Designated as safety issue: No ]
Safety Assessments [ Time Frame: Baseline through week 8 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Global Symptom Assessment, as answered by Investigator and Parent/Guardian [ Time Frame: Baseline through Week 8 ] [ Designated as safety issue: No ]
Sensitivity analyses of the primary endpoint [ Time Frame: Week 4 ] [ Designated as safety issue: No ]
Additional Daily Diary-based symptom Assessments [ Time Frame: At the end of the double-blind treatment period and 30 days after the last dose of study drug. ] [ Designated as safety issue: No ]
Indicators of Growth Parameters [ Time Frame: During and at the end of the Double-blind treatment period and 30 days after the last dose of study drug. ] [ Designated as safety issue: No ]

Enrollment:	162
Study Start Date:	June 2006
Study Completion Date:	May 2007
Primary Completion Date:	May 2007 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: Lansoprazole Microgranules suspension Lansoprazole microgranules 0.2-0.3 mg/kg/day suspension, orally, once daily for up to 28 days for infants less than 10 weeks; Lansoprazole microgranules 1.0-1.5 mg/kg/day suspension, orally, once daily for up to 28 days for infants greater than 10 weeks.
2: Placebo Comparator	Drug: Placebo Lansoprazole placebo-matching suspension, orally, once daily for up to 28 days.

Detailed Description:

This study will be conducted by approximately 20 investigative sites in the U.S. and Poland. Subjects who qualify will be randomized in equal proportions to receive either lansoprazole Pediatric Suspension (0.2-0.3 mg/kg/day in infants <10 weeks of age or 1.0-1.5 mg/kg/day in infants >10 weeks of age) or Placebo. This study consists of three periods: Pretreatment Period of 7-14 days, Double-Blind Treatment Period of 4 weeks (Dosing), and the Post-Treatment Period of 30 days (Follow-Up).

Eligibility

Ages Eligible for Study:	1 Month to 11 Months
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

At least 7 days post-surgery at the time of Screening (Study Visit 1) with no anticipated need for surgery during the study.
Experiencing symptoms of gastroesophageal reflux disease (regurgitation, vomiting or "spitting up," fussing/irritability, feeding refusal, crying during feeding, arching back, poor weight gain, or extraesophageal manifestations) or endoscopy proven reflux disease.
Must continue to have reflux symptoms during the Pretreatment Period despite reducing or eliminating exposure to tobacco smoke, using one positioning and feeding strategy the last 7 days as documented in the Daily Diary.
The infant exhibited crying, fussing, or irritability during or within 1 hour of feeding in >25% of all feedings during the last 4 days of the Pretreatment Period as documented in the Daily Diary.

Exclusion Criteria:

Body weight <2.0 kilogram at Dosing Day 1 of the Double-Blind Treatment Period.
Unstable, congenital or acquired, clinically significant disease of any major organ system (cardiovascular, respiratory, renal, hepatic, metabolic, etc.), including suspected and/or documented culture-proven sepsis.
Coexisting esophageal disease (e.g., eosinophilic esophagitis, viral, bacterial or fungal infection) or caustic or physiochemical trauma to the esophagus.
Any congenital anomaly of the upper gastric intestinal tract that might interfere with gastrointestinal motility, pH, absorption, or active or known history of necrotizing enterocolitis that has been surgically corrected.
Use of a proton pump inhibitor within 30 days prior to Dosing Day 1.
Use of H2 Blockers (i.e. Zantac) within 7 days prior to Dosing Day 1.
Allergy to proton pump inhibitors (i.e. Prilosec, Prevacid).
Use of prokinetics (e.g., metoclopramide) unless on a stable dose for at least 3 days prior to entering the Pretreatment Period.
Unable to obtain stable drug levels after continuous treatment with required drugs including theophylline derivatives, digoxin, phenytoin, phenobarbital, or carbamazepine within the 7 days prior to Dosing Day 1.
Clinically Significant abnormalities in clinical laboratory values.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00324974

Locations

United States, Florida

Tampa, Florida, United States
United States, Illinois

Park Ridge, Illinois, United States
United States, Louisiana

Shreveport, Louisiana, United States
United States, Michigan

Flint, Michigan, United States
United States, Nebraska

Omaha, Nebraska, United States
United States, New York

Buffalo, New York, United States
United States, Ohio

Cincinnati, Ohio, United States

Youngstown, Ohio, United States
United States, Virginia

Vienna, Virginia, United States
Poland

Bialystok, Poland

Cracow, Poland

Katowice, Poland

Lodz, Poland

Wroclaw, Poland

Rzeszow, Poland

Warsawa, Poland

Lublin, Poland

Sponsors and Collaborators

Takeda Global Research & Development Center, Inc.

Investigators

Study Director:

Medical Director

Takeda Global Research & Development Center, Inc.

More Information

For the Prevacid Package Insert, refer to this link: This link exits the ClinicalTrials.gov site

For FDA Safety Alerts and Recalls, refer to this link: This link exits the ClinicalTrials.gov site

Publications of Results:

Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M. Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Assessing the Efficacy and Safety of Proton Pump Inhibitor Lansoprazole in Infants with Symptoms of Gastroesophageal Reflux Disease. J Pediatr. 2008 Dec 1; [Epub ahead of print]

Responsible Party:	Takeda Global Research & Development Center, Inc. ( Sr. VP Clinical Sciences )
Study ID Numbers:	P-GI05-109, EudraCT# 2006-000957-23
Study First Received:	May 9, 2006
Last Updated:	January 13, 2009
ClinicalTrials.gov Identifier:	NCT00324974
Health Authority:	United States: Food and Drug Administration; Poland: Ministry of Health

Keywords provided by Takeda Global Research & Development Center, Inc.:

Gastroesophageal Reflux Disease
infant
lansoprazole oral suspension
PPI

Study placed in the following topic categories:

Deglutition Disorders
Esophageal Motility Disorders
Digestive System Diseases
Esophageal disorder

Gastrointestinal Diseases
Lansoprazole
Esophageal Diseases
Gastroesophageal Reflux

Additional relevant MeSH terms:

Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Anti-Ulcer Agents

Gastrointestinal Agents
Enzyme Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009